Multiple Myeloma Clinical Trial
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
Age > 18 years of age as of start of treatment with BLENREP
Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.
Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
Age > 89 years of age as of start of index therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Durham North Carolina, 27705, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.